<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001513'>Obesity</z:hpo> is an established risk factor for esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>, although the mechanism is unclear </plain></SENT>
<SENT sid="1" pm="."><plain>A pathway from reflux to <z:mp ids='MP_0001845'>inflammation</z:mp> through <z:mpath ids='MPATH_160'>metaplasia</z:mpath> is the dominant hypothesis, and an added role relating to visceral <z:e sem="disease" ids="C0028754" disease_type="Disease or Syndrome" abbrv="">adiposity</z:e> and the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> has been mooted in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> (BE) patients </plain></SENT>
<SENT sid="2" pm="."><plain>Whether BE differs from <z:hpo ids='HP_0002020'>gastroesophageal reflux disease</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e>) in <z:hpo ids='HP_0001513'>obesity</z:hpo> and <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> profiles is unclear, and this was the focus of this study </plain></SENT>
<SENT sid="3" pm="."><plain>Patients with proven BE or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> were randomly selected from the unit data registry and invited to attend for <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> screening, anthropometry studies including segmental body composition analysis, and laboratory tests including fasting <z:chebi fb="23" ids="18059">lipids</z:chebi>, insulin, and C-reactive protein </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">Metabolic syndrome</z:e> was defined using the National Cholesterol Education Program (NCEP) and the International <z:mp ids='MP_0002055'>Diabetes</z:mp> Federation (IDF) criteria </plain></SENT>
<SENT sid="5" pm="."><plain>One hundred and eighteen BE patients and 113 age- and sex-matched <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> controls were studied </plain></SENT>
<SENT sid="6" pm="."><plain>The incidence of <z:hpo ids='HP_0001513'>obesity</z:hpo> (body mass index &gt;30 kg/m(2)) was 36% and 38%, respectively, with the pattern of fat deposition predominantly central and an estimated trunk fat mass of 13 and 14 kg, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>Using the NCEP criteria, <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> was significantly more common in the BE cohort (30% vs 20%, P &lt; 0.05), but there was no significant difference using IDF criteria (42% vs 37%, P= 0.340) </plain></SENT>
<SENT sid="8" pm="."><plain>Central <z:hpo ids='HP_0001513'>obesity</z:hpo> and the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> are common in both Barrett's and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> cohorts, but not significantly different, suggesting that central <z:hpo ids='HP_0001513'>obesity</z:hpo> and the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> does not per se impact on the development of BE in a reflux population </plain></SENT>
<SENT sid="9" pm="."><plain>In BE, the importance of <z:hpo ids='HP_0001513'>obesity</z:hpo> and the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> in disease progression merits further study </plain></SENT>
</text></document>